Immix Biopharma (IMMX) Operating Income (2021 - 2026)
Immix Biopharma (IMMX) reported Operating Income of -$10.8 million for Q1 2026, down 130.71% on a YoY basis from $35.2 million in Q1 2025, and up 0.82% sequentially from -$10.9 million in Q4 2025.
Immix Biopharma (IMMX) Operating Income (2021 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 6 years of Operating Income data on file, last reported at -$10.8 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 130.71% year-over-year to -$10.8 million; the trailing twelve-month figure through Mar 2026 stood at -$36.1 million (down 65.74% YoY), and the FY2025 full-year result was -$30.0 million, down 32.11% from the prior year.
- Operating Income rose to -$10.8 million in Q1 2026, from -$10.9 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$1.3 million in Q1 2022 to a low of -$10.9 million in Q4 2025.
- A 5-year average of -$5.2 million and a median of -$4.7 million in 2024 frame the typical range for Operating Income.
- Across the five-year window, Operating Income sank 718.38% in 2022 and increased 16.23% in 2025, its largest moves.
- Tracing IMMX's Operating Income over 5 years: stood at -$3.8 million in 2022, then slumped by 41.67% to -$5.4 million in 2023, then advanced by 7.23% to -$5.0 million in 2024, then plunged by 118.43% to -$10.9 million in 2025, then advanced by 0.82% to -$10.8 million in 2026.
- Business Quant data shows IMMX's Operating Income at -$10.8 million in Q1 2026, -$10.9 million in Q4 2025, and -$7.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Immix Biopharma | 473.68 Mn | 473.68 Mn | - | -10.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.80 Mn |
| Dec 31, 2025 | -10.89 Mn |
| Sep 30, 2025 | -7.66 Mn |
| Jun 30, 2025 | -6.72 Mn |
| Mar 31, 2025 | -4.68 Mn |
| Dec 31, 2024 | -4.99 Mn |
| Sep 30, 2024 | -7.39 Mn |
| Jun 30, 2024 | -4.70 Mn |
| Mar 31, 2024 | -5.59 Mn |
| Dec 31, 2023 | -5.38 Mn |
| Sep 30, 2023 | -4.52 Mn |
| Jun 30, 2023 | -3.72 Mn |
| Mar 31, 2023 | -2.52 Mn |
| Dec 31, 2022 | -3.79 Mn |
| Sep 30, 2022 | -1.53 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -598,338.00 |
| Sep 30, 2021 | -347,991.00 |
| Jun 30, 2021 | -243,165.00 |